SCHEMBL29460261

SCHEMBL29460261

O=C(NCC[C@@H]1C[C@H]1CO)c1cc2ccccc2[nH]1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.64
▸ ALDH1A1 P00352 3/20 0.64
▸ AKR1C3 P42330 1/20 0.62
▸ HSD17B10 Q99714 3/20 0.60
▸ DRD2 P14416 2/20 0.60
▸ DRD3 P35462 2/20 0.60
▸ HTR2C P28335 1/20 0.58
▸ HDAC1 Q13547 3/20 0.57
▸ HDAC2 Q92769 3/20 0.57
▸ HDAC3 O15379 2/20 0.57
▸ HDAC4 P56524 2/20 0.57
▸ HDAC7 Q8WUI4 2/20 0.57
▸ HDAC10 Q969S8 2/20 0.57
▸ HDAC11 Q96DB2 2/20 0.57
▸ HDAC8 Q9BY41 2/20 0.57
▸ HDAC6 Q9UBN7 2/20 0.57
▸ HDAC9 Q9UKV0 2/20 0.57
▸ HDAC5 Q9UQL6 2/20 0.57
▸ GAA P10253 1/20 0.55
▸ MAPK1 P28482 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29460214 1.00 KDM4E (0.64) KDM4EALDH1A1AKR1C3HSD17B10DRD2
SCHEMBL22533902 1.00 KDM4E (0.64) KDM4EALDH1A1AKR1C3HSD17B10DRD2
SCHEMBL22533897 1.00 KDM4E (0.64) KDM4EALDH1A1AKR1C3HSD17B10DRD2
SCHEMBL22533988 1.00 KDM4E (0.64) KDM4EALDH1A1AKR1C3HSD17B10DRD2
SCHEMBL22533923 0.89 KDM4E (0.59) KDM4EALDH1A1AKR1C3HSD17B10DRD2
SCHEMBL24614023 0.84 KDM4E (0.60) KDM4EALDH1A1AKR1C3HSD17B10DRD2
SCHEMBL24614027 0.84 KDM4E (0.60) KDM4EALDH1A1AKR1C3HSD17B10DRD2
SCHEMBL24614046 0.83 KDM4E (0.65) KDM4EALDH1A1AKR1C3HSD17B10DRD2
SCHEMBL22533909 0.83 KDM4E (0.58) KDM4EALDH1A1AKR1C3HSD17B10DRD2
SCHEMBL22533925 0.83 KDM4E (0.58) KDM4EALDH1A1AKR1C3HSD17B10DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3953350-A1 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF The United States of America, as Represented by The Department of Health and Human Services (US) 2022-02-16 — — EP disclosed
Send feedback